References
Key articles
Knuuti J, Wijns W, Saraste A, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020 Jan 14;41(3):407-77.Full text Abstract
Gulati M, Levy PD, Mukherjee D, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR guideline for the evaluation and diagnosis of chest pain: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation. 2021 Nov 30;144(22):e368-454.Full text Abstract
Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American College of Cardiology joint committee on clinical practice guidelines. Circulation. 2023 Aug 29;148(9):e9-119.Full text Abstract
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation. 2019 Jun 18;139(25):e1082-143.Full text Abstract
Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Thorac Cardiovasc Surg. 2016 Nov;152(5):1243-75. Abstract
Reference articles
1. Marzilli M, Merz CN, Boden WE, et al. Obstructive coronary atherosclerosis and ischemic heart disease: an elusive link! J Am Coll Cardiol. 2012 Sep 11;60(11):951-6.Full text Abstract
2. Pepine CJ, Douglas PS. Rethinking stable ischemic heart disease: is this the beginning of a new era? J Am Coll Cardiol. 2012 Sep 11;60(11):957-9.Full text Abstract
3. Canadian Cardiovascular Society. Canadian Cardiovascular Society grading of angina pectoris. 1976 [internet publication].Full text
4. Roth GA, Johnson C, Abajobir A, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol. 2017 Jul 4;70(1):1-25.Full text Abstract
5. GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017 Sep 16;390(10100):1151-210.Full text Abstract
6. Martin SS, Aday AW, Almarzooq ZI, et al. 2024 heart disease and stroke statistics: a report of US and global data from the American Heart Association. Circulation. 2024 Feb 20;149(8):e347-913.Full text Abstract
7. Lloyd-Jones DM, Larson MG, Beiser A, et al. Lifetime risk of developing coronary heart disease. Lancet. 1999 Jan 9;353(9147):89-92. Abstract
8. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020 Oct 17;396(10258):1204-22.Full text Abstract
9. Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J. 1986 Feb;111(2):383-90. Abstract
10. Cho L, Davis M, Elgendy I, et al. Summary of updated recommendations for primary prevention of cardiovascular disease in women: JACC state-of-the-art review. J Am Coll Cardiol. 2020 May 26;75(20):2602-18.Full text Abstract
11. Mirzaei M, Truswell AS, Taylor R, et al. Coronary heart disease epidemics: not all the same. Heart. 2009 May;95(9):740-6. Abstract
12. Timmis A, Vardas P, Townsend N, et al. European Society of Cardiology: cardiovascular disease statistics 2021. Eur Heart J. 2022 Feb 22;43(8):716-99.Full text Abstract
13. Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med. 2007 Jun 7;356(23):2388-98.Full text Abstract
14. Gaziano JM. Fifth phase of the epidemiologic transition: the age of obesity and inactivity. JAMA. 2010 Jan 20;303(3):275-6. Abstract
15. Chen W, Li Z, Zhao Y, et al. Global and national burden of atherosclerosis from 1990 to 2019: trend analysis based on the Global Burden of Disease Study 2019. Chin Med J (Engl). 2023 Oct 20;136(20):2442-50.Full text Abstract
16. Zdravkovic S, Wienke A, Pedersen NL, et al. Heritability of death from coronary heart disease: a 36-year follow-up of 20 966 Swedish twins. J Intern Med. 2002 Sep;252(3):247-54.Full text Abstract
17. Lloyd-Jones DM, Nam BH, D'Agostino RB Sr, et al. Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA. 2004 May 12;291(18):2204-11.Full text Abstract
18. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Sep 10;140(11):e596-e646.Full text Abstract
19. Havranek EP, Mujahid MS, Barr DA, et al. Social determinants of risk and outcomes for cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2015 Sep 1;132(9):873-98.Full text Abstract
20. Khaing W, Vallibhakara SA, Attia J, et al. Effects of education and income on cardiovascular outcomes: a systematic review and meta-analysis. Eur J Prev Cardiol. 2017 Jul;24(10):1032-42. Abstract
21. Agewall S, Beltrame JF, Reynolds HR, et al. ESC working group position paper on myocardial infarction with non-obstructive coronary arteries. Eur Heart J. 2017 Jan 14;38(3):143-53.Full text Abstract
22. Tamis-Holland JE, Jneid H, Reynolds HR, et al. Contemporary diagnosis and management of patients with myocardial infarction in the absence of obstructive coronary artery disease: a scientific statement from the American Heart Association. Circulation. 2019 Apr 30;139(18):e891-e908.Full text Abstract
23. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020 Jan 14;41(3):407-77.Full text Abstract
24. Gulati M, Levy PD, Mukherjee D, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR guideline for the evaluation and diagnosis of chest pain: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation. 2021 Nov 30;144(22):e368-454.Full text Abstract
25. Ford TJ, Stanley B, Good R, et al. Stratified medical therapy using invasive coronary function testing in angina: the CorMicA trial. J Am Coll Cardiol. 2018 Dec 11;72(23 pt a):2841-55.Full text Abstract
26. Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American College of Cardiology joint committee on clinical practice guidelines. Circulation. 2023 Aug 29;148(9):e9-119.Full text Abstract
27. Kunadian V, Chieffo A, Camici PG, et al. An EAPCI expert consensus document on ischaemia with non-obstructive coronary arteries in collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology and Microcirculation endorsed by Coronary Vasomotor Disorders International Study Group. Eur Heart J. 2020 Oct 1;41(37):3504-20.Full text Abstract
28. Hokimoto S, Kaikita K, Yasuda S, et al. JCS/CVIT/JCC 2023 guideline focused update on diagnosis and treatment of vasospastic angina (coronary spastic angina) and coronary microvascular dysfunction. Circ J. 2023 May 25;87(6):879-936.Full text
29. Hayes SN, Kim ESH, Saw J, et al. Spontaneous coronary artery dissection: current state of the science: a scientific statement from the American Heart Association. Circulation. 2018 May 8;137(19):e523-57.Full text Abstract
30. Falk E, Nakano M, Bentzon JF, et al. Update on acute coronary syndromes: the pathologists' view. Eur Heart J. 2013 Mar;34(10):719-28.Full text Abstract
31. Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med. 2013 May 23;368(21):2004-13. Abstract
32. Gould KL. Does coronary flow trump coronary anatomy? JACC Cardiovasc Imaging. 2009 Aug;2(8):1009-23.Full text Abstract
33. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227-37.Full text Abstract
34. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004 Sep 11-17;364(9438):937-52. Abstract
35. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002 Dec 14;360(9349):1903-13. Abstract
36. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016 Mar 5;387(10022):957-67. Abstract
37. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. J Hypertens. 2014 Dec;32(12):2285-95. Abstract
38. Booth GL, Kapral MK, Fung K, et al. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet. 2006 Jul 1;368(9529):29-36. Abstract
39. Thompson PD, Buchner D, Piña IL, et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation. 2003 Jun 24;107(24):3109-16.Full text Abstract
40. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003 Oct 28;108(17):2154-69.Full text
41. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation. 2019 Jun 18;139(25):e1082-143.Full text Abstract
42. Carrillo-Estrada M, Bobrowski D, Carrasco R, et al. Coronary artery disease in patients with cancer: challenges and opportunities for improvement. Curr Opin Cardiol. 2021 Sep 1;36(5):597-608.Full text Abstract
43. Mitchell JD, Cehic DA, Morgia M, et al. Cardiovascular manifestations from therapeutic radiation: a multidisciplinary expert consensus statement from the International Cardio-Oncology Society. JACC CardioOncol. 2021 Sep 21;3(3):360-80.Full text Abstract
44. Beavers CJ, Rodgers JE, Bagnola AJ, et al. Cardio-oncology drug interactions: a scientific statement from the American Heart Association. Circulation. 2022 Apr 12;145(15):e811-38.Full text Abstract
45. Powell-Wiley TM, Poirier P, Burke LE, et al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021 May 25;143(21):e984-1010.Full text Abstract
46. Bogers RP, Bemelmans WJ, Hoogenveen RT, et al. Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels: a meta-analysis of 21 cohort studies including more than 300 000 persons. Arch Intern Med. 2007 Sep 10;167(16):1720-8.Full text Abstract
47. Rao G, Powell-Wiley TM, Ancheta I, et al. Identification of obesity and cardiovascular risk in ethnically and racially diverse populations: a scientific statement from the American Heart Association. Circulation. 2015 Aug 4;132(5):457-72.Full text
48. Talarico GP, Crosta ML, Giannico MB, et al. Cocaine and coronary artery diseases: a systematic review of the literature. J Cardiovasc Med (Hagerstown). 2017 May;18(5):291-4. Abstract
49. Akasaki Y, Ohishi M. Cerebrovascular and cardiovascular diseases caused by drugs of abuse. Hypertens Res. 2020 May;43(5):363-71. Abstract
50. US Preventive Services Task Force., Curry SJ, Krist AH, et al. Risk assessment for cardiovascular disease with nontraditional risk factors: US Preventive Services Task Force recommendation statement. JAMA. 2018 Jul 17;320(3):272-80.Full text Abstract
51. Kaufman JD, Adar SD, Barr RG, et al. Association between air pollution and coronary artery calcification within six metropolitan areas in the USA (the Multi-Ethnic Study of Atherosclerosis and Air Pollution): a longitudinal cohort study. Lancet. 2016 Aug 13;388(10045):696-704. Abstract
52. Hoek G, Krishnan RM, Beelen R, et al. Long-term air pollution exposure and cardio-respiratory mortality: a review. Environ Health. 2013 May 28;12(1):43.Full text Abstract
53. Rajagopalan S, Landrigan PJ. Pollution and the heart. N Engl J Med. 2021 Nov 11;385(20):1881-92.Full text
54. Alexeeff SE, Liao NS, Liu X, et al. Long-term PM(2.5) exposure and risks of ischemic heart disease and stroke events: review and meta-analysis. J Am Heart Assoc. 2021 Jan 5;10(1):e016890.Full text Abstract
55. McGuinn LA, Ward-Caviness CK, Neas LM, et al. Association between satellite-based estimates of long-term PM2.5 exposure and coronary artery disease. Environ Res. 2016 Feb;145:9-17. Abstract
56. Lloyd-Jones DM, Allen NB, Anderson CAM, et al. Life's essential 8: updating and enhancing the American Heart Association's construct of cardiovascular health: a presidential advisory from the American Heart Association. Circulation. 2022 Aug 2;146(5):e18-e43.Full text Abstract
57. US Preventive Services Task Force. Healthy diet and physical activity for cardiovascular disease prevention in adults with cardiovascular risk factors: behavioral counseling interventions. Nov 2020 [internet publication].Full text
58. US Preventive Services Task Force. Healthy diet and physical activity for cardiovascular disease prevention in adults without cardiovascular disease risk factors: behavioral counseling interventions. Jul 2022 [internet publication].Full text
59. World Health Organization. WHO guidelines on physical activity and sedentary behaviour. Nov 2020 [internet publication].Full text
60. US Preventive Services Task Force. Statin use for the primary prevention of cardiovascular disease in adults: preventive medication. Aug 2022 [internet publication].Full text
61. National Institute for Health and Care Excellence. Cardiovascular disease: risk assessment and reduction, including lipid modification. Dec 2023 [internet publication].Full text
62. US Preventive Services Task Force. Aspirin use to prevent cardiovascular disease: preventive medication. April 2022 [internet publication].Full text
63. Diamond GA, Forrester JS. Analysis of probability as an aid in the clinical diagnosis of coronary-artery disease. N Engl J Med. 1979 Jun 14;300(24):1350-8. Abstract
64. Genders TS, Steyerberg EW, Alkadhi H, et al. A clinical prediction rule for the diagnosis of coronary artery disease: validation, updating, and extension. Eur Heart J. 2011 Jun;32(11):1316-30.Full text Abstract
65. Juarez-Orozco LE, Saraste A, Capodanno D, et al. Impact of a decreasing pre-test probability on the performance of diagnostic tests for coronary artery disease. Eur Heart J Cardiovasc Imaging. 2019 Nov 1;20(11):1198-207.Full text Abstract
66. Anderson HVS, Masri SC, Abdallah MS, et al. 2022 ACC/AHA key data elements and definitions for chest pain and acute myocardial infarction: A report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Data Standards. Circ Cardiovasc Qual Outcomes. 2022 Oct;15(10):e000112.Full text Abstract
67. Chun AA, McGee SR. Bedside diagnosis of coronary artery disease: a systematic review. Am J Med. 2004 Sep 1;117(5):334-43. Abstract
68. Levine HJ. Difficult problems in the diagnosis of chest pain. Am Heart J. 1980 Jul;100(1):108-18. Abstract
69. Multimodality Writing Group for Chronic Coronary Disease, Winchester DE, Maron DJ, et al. ACC/AHA/ASE/ASNC/ASPC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2023 multimodality appropriate use criteria for the detection and risk assessment of chronic coronary disease. J Am Coll Cardiol. 2023 Jun 27;81(25):2445-67.Full text Abstract
70. Pryor DB, Shaw L, McCants CB, et al. Value of the history and physical in identifying patients at increased risk for coronary artery disease. Ann Intern Med. 1993 Jan 15;118(2):81-90. Abstract
71. Weiner DA, Ryan TJ, McCabe CH, et al. Exercise stress testing. Correlations among history of angina, ST-segment response and prevalence of coronary-artery disease in the Coronary Artery Surgery Study (CASS). N Engl J Med. 1979 Aug 2;301(5):230-5. Abstract
72. Agha AM, Pacor J, Grandhi GR, et al. The prognostic value of CAC zero among individuals presenting with chest pain: a meta-analysis. JACC Cardiovasc Imaging. 2022 Oct;15(10):1745-57.Full text Abstract
73. Douglas PS, Hoffmann U, Patel MR, et al; PROMISE Investigators. Outcomes of anatomical versus functional testing for coronary artery disease. N Engl J Med. 2015 Apr 2;372(14):1291-300.Full text Abstract
74. Skelly AC, Hashimoto R, Buckley DI, et al. Noninvasive testing for coronary artery disease. Comparative effectiveness reviews, no. 171. Rockville, MD: Agency for Healthcare Research and Quality (US); 2016:1-363.Full text Abstract
75. SCOT-HEART Investigators. CT coronary angiography in patients with suspected angina due to coronary heart disease (SCOT-HEART): an open-label, parallel-group, multicentre trial. Lancet. 2015 Jun 13;385(9985):2383-91.Full text Abstract
76. McKavanagh P, Lusk L, Ball PA, et al. A comparison of cardiac computerized tomography and exercise stress electrocardiogram test for the investigation of stable chest pain: the clinical results of the CAPP randomized prospective trial. Eur Heart J Cardiovasc Imaging. 2015 Apr;16(4):441-8.Full text Abstract
77. Min JK, Koduru S, Dunning AM, et al. Coronary CT angiography versus myocardial perfusion imaging for near-term quality of life, cost and radiation exposure: a prospective multicenter randomized pilot trial. J Cardiovasc Comput Tomogr. 2012 Jul-Aug;6(4):274-83. Abstract
78. Zito A, Galli M, Biondi-Zoccai G, et al. Diagnostic strategies for the assessment of suspected stable coronary artery disease : a systematic review and meta-analysis. Ann Intern Med. 2023 Jun;176(6):817-26. Abstract
79. Okin PM, Kligfield P. Gender-specific criteria and performance of the exercise electrocardiogram. Circulation. 1995 Sep 1;92(5):1209-16.Full text Abstract
80. Shaw LJ, Mieres JH, Hendel RH, et al; WOMEN Trial Investigators. Comparative effectiveness of exercise electrocardiography with or without myocardial perfusion single photon emission computed tomography in women with suspected coronary artery disease: results from the What Is the Optimal Method for Ischemia Evaluation in Women (WOMEN) trial. Circulation. 2011 Sep 13;124(11):1239-49.Full text Abstract
81. Shaw LJ, Peterson ED, Shaw LK, et al. Use of a prognostic treadmill score in identifying diagnostic coronary disease subgroups. Circulation. 1998 Oct 20;98(16):1622-30. Abstract
82. Lauer MS, Pothier CE, Magid DJ, et al. An externally validated model for predicting long-term survival after exercise treadmill testing in patients with suspected coronary artery disease and a normal electrocardiogram. Ann Intern Med. 2007 Dec 18;147(12):821-8. Abstract
83. Hachamovitch R, Berman DS, Kiat H, et al. Exercise myocardial perfusion SPECT in patients without known coronary artery disease: incremental prognostic value and use in risk stratification. Circulation. 1996 Mar 1;93(5):905-14. Abstract
84. Marwick TH, Case C, Vasey C, et al. Prediction of mortality by exercise echocardiography: a strategy for combination with the Duke treadmill score. Circulation. 2001 May 29;103(21):2566-71. Abstract
85. Hoffmann U, Ferencik M, Udelson JE, et al; PROMISE Investigators. Prognostic value of noninvasive cardiovascular testing in patients with stable chest pain: insights from the PROMISE trial (Prospective Multicenter Imaging Study for Evaluation of Chest Pain). Circulation. 2017 Jun 13;135(24):2320-32.Full text Abstract
86. Xie JX, Cury RC, Leipsic J, et al. The Coronary Artery Disease-Reporting and Data System (CAD-RADS): prognostic and clinical implications associated with standardized coronary computed tomography angiography reporting. JACC Cardiovasc Imaging. 2018 Jan;11(1):78-89. Abstract
87. Andreini D, Pontone G, Mushtaq S, et al. A long-term prognostic value of coronary CT angiography in suspected coronary artery disease. JACC Cardiovasc Imaging. 2012 Jul;5(7):690-701.Full text Abstract
88. Froelicher VF, Lehmann KG, Thomas R, et al. The electrocardiographic exercise test in a population with reduced workup bias: diagnostic performance, computerized interpretation, and multivariable prediction. Veterans Affairs Cooperative Study in Health Services #016 (QUEXTA) Study Group. Quantitative exercise testing and angiography. Ann Intern Med. 1998 Jun 15;128(12 pt 1):965-74. Abstract
89. National Institute for Health and Care Excellence. Recent-onset chest pain of suspected cardiac origin: assessment and diagnosis. Nov 2016 [internet publication].Full text
90. Scottish Intercollegiate Guidelines Network. Management of stable angina: a national clinical guideline. Apr 2018 [internet publication].Full text
91. SCOT-HEART Investigators., Newby DE, Adamson PD, et al. Coronary CT angiography and 5-year risk of myocardial infarction. N Engl J Med. 2018 Sep 6;379(10):924-33.Full text Abstract
92. Maddox TM, Stanislawski MA, Grunwald GK, et al. Nonobstructive coronary artery disease and risk of myocardial infarction. JAMA. 2014 Nov 5;312(17):1754-63.Full text Abstract
93. Tonino PA, Fearon WF, De Bruyne B, et al. Angiographic versus functional severity of coronary artery stenoses in the FAME study: fractional flow reserve versus angiography in multivessel evaluation. J Am Coll Cardiol. 2010 Jun 22;55(25):2816-21.Full text Abstract
94. Pijls NH, De Bruyne B, Peels K, et al. Measurement of fractional flow reserve to assess the functional severity of coronary-artery stenoses. N Engl J Med. 1996 Jun 27;334(26):1703-8.Full text Abstract
95. Barbato E, Toth GG, Johnson NP, et al. A prospective natural history study of coronary atherosclerosis using fractional flow reserve. J Am Coll Cardiol. 2016 Nov 29;68(21):2247-55.Full text Abstract
96. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 Jan 1;41(1):111-88.Full text Abstract
97. Winther S, Schmidt SE, Mayrhofer T, et al. Incorporating coronary calcification into pre-test assessment of the likelihood of coronary artery disease. J Am Coll Cardiol. 2020 Nov 24;76(21):2421-32.Full text Abstract
98. Villines TC, Hulten EA, Shaw LJ, et al; CONFIRM Registry Investigators. Prevalence and severity of coronary artery disease and adverse events among symptomatic patients with coronary artery calcification scores of zero undergoing coronary computed tomography angiography: results from the CONFIRM (Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter) registry. J Am Coll Cardiol. 2011 Dec 6;58(24):2533-40.Full text Abstract
99. Wieske V, Walther M, Dubourg B, et al. Computed tomography angiography versus Agatston score for diagnosis of coronary artery disease in patients with stable chest pain: individual patient data meta-analysis of the international COME-CCT Consortium. Eur Radiol. 2022 Aug;32(8):5233-45.Full text Abstract
100. Hamon M, Geindreau D, Guittet L, et al. Additional diagnostic value of new CT imaging techniques for the functional assessment of coronary artery disease: a meta-analysis. Eur Radiol. 2019 Jun;29(6):3044-61. Abstract
101. Celeng C, Leiner T, Maurovich-Horvat P, et al. Anatomical and functional computed tomography for diagnosing hemodynamically significant coronary artery disease: a meta-analysis. JACC Cardiovasc Imaging. 2019 Jul;12(7 pt 2):1316-25.Full text Abstract
102. Patel AR, Bamberg F, Branch K, et al. Society of cardiovascular computed tomography expert consensus document on myocardial computed tomography perfusion imaging. J Cardiovasc Comput Tomogr. 2020 Jan - Feb;14(1):87-100. Abstract
103. Culić V, Eterović D, Mirić D, et al. Symptom presentation of acute myocardial infarction: influence of sex, age, and risk factors. Am Heart J. 2002 Dec;144(6):1012-7. Abstract
104. Shaw LJ, Bairey Merz CN, Pepine CJ, et al. Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) study: part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. J Am Coll Cardiol. 2006 Feb 7;47(3 suppl):S4-S20.Full text Abstract
105. Canto JG, Goldberg RJ, Hand MM, et al. Symptom presentation of women with acute coronary syndromes: myth vs reality. Arch Intern Med. 2007 Dec 10;167(22):2405-13.Full text Abstract
106. Junghans C, Sekhri N, Zaman MJ, et al. Atypical chest pain in diabetic patients with suspected stable angina: impact on diagnosis and coronary outcomes. Eur Heart J Qual Care Clin Outcomes. 2015 Jul 1;1(1):37-43.Full text Abstract
107. Pontone G, Baggiano A, Andreini D, et al. Stress computed tomography perfusion versus fractional flow reserve CT derived in suspected coronary artery disease: the PERFECTION study. JACC Cardiovasc Imaging. 2019 Aug;12(8 pt 1):1487-97.Full text Abstract
108. Kass SM, Williams PM, Reamy BV. Pleurisy. Am Fam Physician. 2007 May 1;75(9):1357-64. Abstract
109. Sutton FM, Graham DY, Goodgame RW. Infectious esophagitis. Gastrointest Endosc Clin N Am. 1994 Oct;4(4):713-29. Abstract
110. Kikendall JW. Pill esophagitis. J Clin Gastroenterol. 1999 Jun;28(4):298-305. Abstract
111. Richter JE. Oesophageal motility disorders. Lancet. 2001 Sep 8;358(9284):823-8. Abstract
112. Richter JE. Gastrooesophageal reflux disease. Best Pract Res Clin Gastroenterol. 2007;21(4):609-31. Abstract
113. Mackay S, Dillane P. Biliary pain. Aust Fam Physician. 2004 Dec;33(12):977-81.Full text Abstract
114. Sanders G, Kingsnorth AN. Gallstones. BMJ. 2007 Aug 11;335(7614):295-9. Abstract
115. Caddy GR, Tham TC. Gallstone disease: symptoms, diagnosis, and endoscopic management of common bile duct stones. Best Pract Res Clin Gastroenterol. 2006;20(6):1085-101. Abstract
116. Ramakrishnan K, Salinas RC. Peptic ulcer disease. Am Fam Physician. 2007 Oct 1;76(7):1005-12. Abstract
117. Chakrabarty S, Zoorob R. Fibromyalgia. Am Fam Physician. 2007 Jul 15;76(2):247-54. Abstract
118. Hassett G, Barnsley L. Pain referral from the sternoclavicular joint: a study in normal volunteers. Rheumatology (Oxford). 2001 Aug;40(8):859-62.Full text Abstract
119. Wareham DW, Breuer J. Herpes zoster. BMJ. 2007 Jun 9;334(7605):1211-5. Abstract
120. Gale CK, Oakley-Browne M. Generalized anxiety disorder. Am Fam Physician. 2003 Jan 1;67(1):135-8.Full text Abstract
121. Weinstein RS. Panic disorder. Am Fam Physician. 1995 Nov 15;52(7):2055-63, 2067-8. Abstract
122. Wolk MJ, Bailey SR, Doherty JU, et al. ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 multimodality appropriate use criteria for the detection and risk assessment of stable ischemic heart disease. J Am Coll Cardiol. 2014 Feb 4;63(4):380-406.Full text Abstract
123. American College of Radiology. ACR appropriateness criteria: chronic chest pain - high probability of coronary artery disease. 2021 [internet publication].Full text
124. Pellikka PA, Arruda-Olson A, Chaudhry FA, et al. Guidelines for performance, interpretation, and application of stress echocardiography in ischemic heart disease: from the American Society of Echocardiography. J Am Soc Echocardiogr. 2020 Jan;33(1):1-41.e8.Full text Abstract
125. American College of Radiology. ACR appropriateness criteria: acute nonspecific chest pain-low probability of coronary artery disease. 2020 [internet publication].Full text
126. American College of Radiology. ACR appropriateness criteria: asymptomatic patient at risk for coronary artery disease. 2020 [internet publication].Full text
127. American College of Radiology. ACR appropriateness criteria: chronic chest pain - noncardiac etiology unlikely: low to intermediate probability of coronary artery disease. 2018 [internet publication].Full text
128. Mieres JH, Gulati M, Bairey Merz N, et al; American Heart Association Cardiac Imaging Committee of the Council on Clinical Cardiology and the Cardiovascular Imaging and Intervention Committee of the Council on Cardiovascular Radiology and Intervention. Role of noninvasive testing in the clinical evaluation of women with suspected ischemic heart disease: a consensus statement from the American Heart Association. Circulation. 2014 Jul 22;130(4):350-79.Full text Abstract
129. Edvardsen T, Asch FM, Davidson B, et al. Non-invasive imaging in coronary syndromes: recommendations of the European Association of Cardiovascular Imaging and the American Society of Echocardiography, in collaboration with the American Society of Nuclear Cardiology, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. Eur Heart J Cardiovasc Imaging. 2022 Jan 24;23(2):e6-33.Full text Abstract
130. Nakano S, Kohsaka S, Chikamori T, et al. JCS 2022 guideline focused update on diagnosis and treatment in patients with stable coronary artery disease. Circ J. 2022 Apr 25;86(5):882-915.Full text
131. Dibben G, Faulkner J, Oldridge N, et al. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev. 2021 Nov 6;(11):CD001800.Full text Abstract
132. McDonagh ST, Dalal H, Moore S, et al. Home-based versus centre-based cardiac rehabilitation. Cochrane Database Syst Rev. 2023 Oct 27;10(10):CD007130. Abstract
133. Thomas RJ, Beatty AL, Beckie TM, et al. Home-based cardiac rehabilitation: a scientific statement from the American Association of Cardiovascular and Pulmonary Rehabilitation, the American Heart Association, and the American College of Cardiology. Circulation. 2019 Jul 2;140(1):e69-89.Full text Abstract
134. Golbus JR, Lopez-Jimenez F, Barac A, et al. Digital technologies in cardiac rehabilitation: a science advisory from the American Heart Association. Circulation. 2023 Jul 4;148(1):95-107.Full text Abstract
135. Paluch AE, Boyer WR, Franklin BA, et al. Resistance exercise training in individuals with and without cardiovascular disease: 2023 update: a scientific statement from the American Heart Association. Circulation. 2024 Jan 16;149(3):e217-31.Full text Abstract
136. Delgado-Lista J, Alcala-Diaz JF, Torres-Peña JD, et al. Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial. Lancet. 2022 May 14;399(10338):1876-85. Abstract
137. Hooper L, Martin N, Jimoh OF, et al. Reduction in saturated fat intake for cardiovascular disease. Cochrane Database Syst Rev. 2020 Aug 21;8(8):CD011737.Full text Abstract
138. Abdelhamid AS, Brown TJ, Brainard JS, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2020 Feb 29;3(3):CD003177.Full text Abstract
139. Khan SU, Lone AN, Khan MS, et al. Effect of omega-3 fatty acids on cardiovascular outcomes: a systematic review and meta-analysis. EClinicalMedicine. 2021 Jul 8:38:100997.Full text Abstract
140. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA. 2003 Jul 2;290(1):86-97. Abstract
141. IARC. IARC handbooks of cancer prevention: tobacco control. Volume 11: reversal of risk after quitting smoking. Lyon, France: International Agency for Research on Cancer; 2007.Full text
142. Wu AD, Lindson N, Hartmann-Boyce J, et al. Smoking cessation for secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2022 Aug 8;8(8):CD014936.Full text Abstract
143. Lichtman JH, Bigger JT Jr, Blumenthal JA, et al. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. Circulation. 2008 Oct 21;118(17):1768-75.Full text Abstract
144. Tully PJ, Ang SY, Lee EJ, et al. Psychological and pharmacological interventions for depression in patients with coronary artery disease. Cochrane Database Syst Rev. 2021 Dec 15;12(12):CD008012.Full text Abstract
145. Kwong JC, Schwartz KL, Campitelli MA, et al. Acute myocardial infarction after laboratory-confirmed influenza infection. N Engl J Med. 2018 Jan 25;378(4):345-53.Full text Abstract
146. Udell JA, Zawi R, Bhatt DL, et al. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA. 2013 Oct 23;310(16):1711-20.Full text Abstract
147. Clar C, Oseni Z, Flowers N, et al. Influenza vaccines for preventing cardiovascular disease. Cochrane Database Syst Rev. 2015 May 5;2015(5):CD005050.Full text Abstract
148. Yedlapati SH, Khan SU, Talluri S, et al. Effects of influenza vaccine on mortality and cardiovascular outcomes in patients with cardiovascular disease: a systematic review and meta-analysis. J Am Heart Assoc. 2021 Mar 16;10(6):e019636.Full text Abstract
149. Barbetta LMDS, Correia ETO, Gismondi RAOC, et al. Influenza vaccination as prevention therapy for stable coronary artery disease and acute coronary syndrome: a meta-analysis of randomized trials. Am J Med. 2023 May;136(5):466-75. Abstract
150. Melgar M, Britton A, Roper LE, et al. Use of respiratory syncytial virus vaccines in older adults: recommendations of the advisory committee on immunization practices - United States, 2023. MMWR Morb Mortal Wkly Rep. 2023 Jul 21;72(29):793-801.Full text Abstract
151. Baigent C, Blackwell L, Collins R, et al; Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009 May 30;373(9678):1849-60.Full text Abstract
152. Yoo SGK, Chung GS, Bahendeka SK, et al. Aspirin for secondary prevention of cardiovascular disease in 51 low-, middle-, and high-income countries. JAMA. 2023 Aug 22;330(8):715-24.Full text Abstract
153. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002 Jan 12;324(7329):71-86.Full text Abstract
154. Serebruany VL, Steinhubl SR, Berger PB, et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol. 2005 May 15;95(10):1218-22. Abstract
155. Jones WS, Mulder H, Wruck LM, et al. Comparative effectiveness of aspirin dosing in cardiovascular disease. N Engl J Med. 2021 May 27;384(21):1981-90.Full text Abstract
156. CAPRIE Steering Committee. A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events. Lancet. 1996 Nov 16;348(9038):1329-39. Abstract
157. Bhatt DL, Fox KA, Hacke W, et al; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006 Apr 20;354(16):1706-17.Full text Abstract
158. Squizzato A, Bellesini M, Takeda A, et al. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events. Cochrane Database Syst Rev. 2017 Dec 14;(12):CD005158.Full text Abstract
159. Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Thorac Cardiovasc Surg. 2016 Nov;152(5):1243-75. Abstract
160. Valgimigli M, Bueno H, Byrne RA, et al; ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018 Jan 14;39(3):213-60.Full text Abstract
161. Guo H, Ye Z, Huang R. Clinical outcomes of concomitant use of proton pump inhibitors and dual antiplatelet therapy: a systematic review and meta-analysis. Front Pharmacol. 2021;12:694698.Full text Abstract
162. Connolly SJ, Eikelboom JW, Bosch J, et al; COMPASS Investigators. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018 Jan 20;391(10117):205-18. Abstract
163. Kernis SJ, Harjai KJ, Stone GW, et al. Does beta-blocker therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty? J Am Coll Cardiol. 2004 May 19;43(10):1773-9.Full text Abstract
164. Tepper D. Frontiers in congestive heart failure: effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Congest Heart Fail. 1999 Jul-Aug;5(4):184-5. Abstract
165. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996 May 23;334(21):1349-55.Full text Abstract
166. Leizorovicz A, Lechat P, Cucherat M, et al. Bisoprolol for the treatment of chronic heart failure: a meta-analysis on individual data of two placebo-controlled studies - CIBIS and CIBIS II. Cardiac Insufficiency Bisoprolol Study. Am Heart J. 2002 Feb;143(2):301-7. Abstract
167. Bangalore S, Makani H, Radford M, et al. Clinical outcomes with β-blockers for myocardial infarction: a meta-analysis of randomized trials. Am J Med. 2014 Oct;127(10):939-53.Full text Abstract
168. Sorbets E, Steg PG, Young R, et al. β-blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study. Eur Heart J. 2019 May 7;40(18):1399-407.Full text Abstract
169. Dondo TB, Hall M, West RM, et al. β-blockers and mortality after acute myocardial infarction in patients without heart failure or ventricular dysfunction. J Am Coll Cardiol. 2017 Jun 6;69(22):2710-20.Full text Abstract
170. Kim J, Kang D, Park H, et al. Long-term β-blocker therapy and clinical outcomes after acute myocardial infarction in patients without heart failure: nationwide cohort study. Eur Heart J. 2020 Oct 1;41(37):3521-9.Full text Abstract
171. Safi S, Sethi NJ, Korang SK, et al. Beta-blockers in patients without heart failure after myocardial infarction. Cochrane Database Syst Rev. 2021 Nov 5;11(11):CD012565.Full text Abstract
172. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993 Oct 2;342(8875):821-8. Abstract
173. Pfeffer MA, Braunwald E, Moyé LA, et al; The SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction - results of the survival and ventricular enlargement trial. N Engl J Med. 1992 Sep 3;327(10):669-77.Full text Abstract
174. Køber L, Torp-Pedersen C, Carlsen JE, et al; Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1995 Dec 21;333(25):1670-6.Full text Abstract
175. Yusuf S, Sleight P, Pogue J, et al; The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000 Jan 20;342(3):145-53.Full text Abstract
176. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003 Sep 6;362(9386):782-8. Abstract
177. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000 Jan 22;355(9200):253-9. Abstract
178. Baigent C, Blackwell L, Emberson J, et al; Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010 Nov 13;376(9753):1670-81.Full text Abstract
179. Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2019 Feb 2;393(10170):407-15.Full text Abstract
180. Newman CB, Preiss D, Tobert JA, et al. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2019 Feb;39(2):e38-e81.Full text Abstract
181. Hong SJ, Lee YJ, Lee SJ, et al. Treat-to-target or high-intensity statin in patients with coronary artery disease: a randomized clinical trial. JAMA. 2023 Apr 4;329(13):1078-87.Full text Abstract
182. Writing Committee, Lloyd-Jones DM, Morris PB, et al. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022 Oct 4;80(14):1366-1418.Full text Abstract
183. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019 Jan 3;380(1):11-22.Full text Abstract
184. Whelton PK, Carey RM, Aronow WS, et al; American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension. 2018 Jun;71(6):e13-115.Full text Abstract
185. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018 Sep 1;39(33):3021-104.Full text Abstract
186. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009 May 19;338:b1665.Full text Abstract
187. Arnold SV, Bhatt DL, Barsness GW, et al. Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association. Circulation. 2020 May 12;141(19):e779-806.Full text Abstract
188. Zinman B, Wanner C, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28. Abstract
189. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017 Aug 17;377(7):644-57.Full text Abstract
190. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016 Jul 28;375(4):311-22.Full text Abstract
191. Marso SP, Bain SC, Consoli A, et al; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016 Nov 10;375(19):1834-44.Full text Abstract
192. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019 Jul 13;394(10193):121-30. Abstract
193. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022 Nov 1;45(11):2753-86.Full text Abstract
194. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023 Dec 14;389(24):2221-32. Abstract
195. Maruthur NM, Tseng E, Hutfless S, et al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2016 Jun 7;164(11):740-51. Abstract
196. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005 Dec 22;353(25):2643-53.Full text Abstract
197. Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004 Sep 21;141(6):421-31. Abstract
198. Patel A, MacMahon S, Chalmers J, et al; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008 Jun 12;358(24):2560-72.Full text Abstract
199. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009 Jan 8;360(2):129-39.Full text Abstract
200. Gerstein HC, Miller ME, Byington RP, et al; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008 Jun 12;358(24):2545-59.Full text Abstract
201. Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009 May 23;373(9677):1765-72. Abstract
202. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ. 2011 Jul 26;343:d4169.Full text Abstract
203. Hemmingsen B, Lund SS, Gluud C, et al. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ. 2011 Nov 24;343:d6898.Full text Abstract
204. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008 Oct 9;359(15):1577-89.Full text Abstract
205. National Institute for Health and Care Excellence. Stable angina: management. Aug 2016 [internet publication].Full text
206. Vandergoten P, Benit E, Dendale P. Prinzmetal's variant angina: three case reports and a review of the literature. Acta Cardiol. 1999 Apr;54(2):71-6. Abstract
207. Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation. 2022 Jan 18;145(3):e18-e114.Full text Abstract
208. Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2019 Jan 7;40(2):87-165.Full text Abstract
209. Patel MR, Calhoon JH, Dehmer GJ, et al. ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017 Appropriate Use Criteria for coronary revascularization in patients with stable ischemic heart disease. J Am Coll Cardiol. 2017;69:2212-41.Full text Abstract
210. Hueb W, Lopes N, Gersh BJ, et al. Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation. 2010 Sep 7;122(10):949-57.Full text Abstract
211. Spertus JA, Jones PG, Maron DJ, et al. Health-status outcomes with invasive or conservative care in coronary disease. N Engl J Med. 2020 Apr 9;382(15):1408-19.Full text Abstract
212. Bangalore S, Maron DJ, Stone GW, et al. Routine revascularization versus initial medical therapy for stable ischemic heart disease: a systematic review and meta-analysis of randomized trials. Circulation. 2020 Sep;142(9):841-57.Full text Abstract
213. Al-Lamee R, Thompson D, Dehbi HM, et al; ORBITA Investigators. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet. 2018 Jan 6;391(10115):31-40. Abstract
214. Boden WE, O'Rourke RA, Teo KK, et al; COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007 Apr 12;356(15):1503-16.Full text Abstract
215. Sedlis SP, Hartigan PM, Teo KK, et al; COURAGE Trial Investigators. Effect of PCI on long-term survival in patients with stable ischemic heart disease. N Engl J Med. 2015 Nov 12;373(20):1937-46.Full text Abstract
216. Maron DJ, Hochman JS, Reynolds HR, et al. Initial invasive or conservative strategy for stable coronary disease. N Engl J Med. 2020 Apr 9;382(15):1395-407.Full text Abstract
217. Navarese EP, Lansky AJ, Kereiakes DJ, et al. Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis. Eur Heart J. 2021 Dec 1;42(45):4638-51.Full text Abstract
218. Varnauskas E. Twelve-year follow-up of survival in the randomized European Coronary Surgery Study. N Engl J Med. 1988 Aug 11;319(6):332-7. Abstract
219. The VA Coronary Artery Bypass Surgery Cooperative Study Group. Eighteen-year follow-up in the Veterans Affairs Cooperative Study of Coronary Artery Bypass Surgery for stable angina. Circulation. 1992 Jul;86(1):121-30.Full text Abstract
220. Passamani E, Davis KB, Gillespie MJ, Killip T. A randomized trial of coronary artery bypass surgery. Survival of patients with a low ejection fraction. N Engl J Med. 1985 Jun 27;312(26):1665-71. Abstract
221. De Bruyne B, Fearon WF, Pijls NH, et al; FAME 2 Trial Investigators. Fractional flow reserve-guided PCI for stable coronary artery disease. N Engl J Med. 2014 Sep 25;371(13):1208-17.Full text Abstract
222. Xaplanteris P, Fournier S, Pijls NHJ, et al. Five-year outcomes with PCI guided by fractional flow reserve. N Engl J Med. 2018 Jul 19;379(3):250-9.Full text Abstract
223. Zimmermann FM, Omerovic E, Fournier S, et al. Fractional flow reserve-guided percutaneous coronary intervention vs. medical therapy for patients with stable coronary lesions: meta-analysis of individual patient data. Eur Heart J. 2019 Jan 7;40(2):180-6.Full text Abstract
224. Ridker PM, Manson JE, Gaziano JM, et al. Low-dose aspirin therapy for chronic stable angina. A randomized, placebo-controlled clinical trial. Ann Intern Med. 1991 May 15;114(10):835-9. Abstract
225. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994 Jan 8;308(6921):81-106.Full text Abstract
226. Parker JD, Parker JO. Nitrate therapy for stable angina pectoris. N Engl J Med. 1998 Feb 19;338(8):520-31. Abstract
227. Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020 Nov 5;383(19):1838-47.Full text Abstract
228. Fiolet ATL, Opstal TSJ, Mosterd A, et al. Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials. Eur Heart J. 2021 Jul 21;42(28):2765-75.Full text Abstract
229. Medicines and Healthcare products Regulatory Agency. Nicorandil (Ikorel): now second-line treatment for angina - risk of ulcer complications. Jan 2016 [internet publication].Full text
230. Danchin N, Marzilli M, Parkhomenko A, et al. Efficacy comparison of trimetazidine with therapeutic alternatives in stable angina pectoris: a network meta-analysis. Cardiology. 2011;120(2):59-72. Abstract
231. Ajabnoor A, Mukhtar A. Effect of trimetazidine on the functional capacity of ischemic heart disease patients not suitable for revascularization: meta-analysis of randomized controlled trials. PLoS One. 2022 Feb 11;17(2):e0263932.Full text Abstract
232. Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023 Apr 13;388(15):1353-64. Abstract
233. Nissen SE, Menon V, Nicholls SJ, et al. Bempedoic acid for primary prevention of cardiovascular events in statin-intolerant patients. JAMA. 2023 Jul 11;330(2):131-40.Full text Abstract
234. Nicholls SJ, Nelson AJ, Lincoff AM, et al. Impact of bempedoic acid on total cardiovascular events: a prespecified analysis of the CLEAR outcomes randomized clinical trial. JAMA Cardiol. 2024 Mar 1;9(3):245-53. Abstract
235. Verheye S, Jolicoeur EM, Behan MW, et al. Efficacy of a device to narrow the coronary sinus in refractory angina. N Engl J Med. 2015 Feb 5;372(6):519-27.Full text Abstract
236. Primary Panel:, Bainey KR, Marquis-Gravel G, et al. Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology 2023 focused update of the guidelines for the use of antiplatelet therapy. Can J Cardiol. 2024 Feb;40(2):160-81.Full text Abstract
237. Writing Committee, Birtcher KK, Allen LA, et al. 2022 ACC expert consensus decision pathway for integrating atherosclerotic cardiovascular disease and multimorbidity treatment: a framework for pragmatic, patient-centered care: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023 Jan 24;81(3):292-317.Full text Abstract
238. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update. Circulation. 2011 Nov 29;124(22):2458-73.Full text Abstract
239. Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women - 2011 update: a guideline from the American Heart Association. Circulation. 2011 Mar 22;123(11):1243-62.Full text Abstract
240. Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic radiology and oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229-361.Full text Abstract
241. Mesnier J, Ducrocq G, Danchin N, et al. International observational analysis of evolution and outcomes of chronic stable angina: the multinational CLARIFY study. Circulation. 2021 Aug 17;144(7):512-23.Full text Abstract
242. Ghisi GL, Abdallah F, Grace SL, et al. A systematic review of patient education in cardiac patients: do they increase knowledge and promote health behavior change? Patient Educ Couns. 2014 May;95(2):160-74. Abstract
Use of this content is subject to our disclaimer